EGFR and lung adenocarcinoma: These mutations are particularly prevalent among females, non-smokers, or former light smokers.1 Targeting those actionable mutations with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, afatinib, and osimertinib, has shown impressive responses rates of 70–75% in patients with lung adenocarcinoma, with notable improvements in progression free survival ranging from 10 to 14 months when compared to standard chemotherapy.2–5